Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. RESEARCH DESIGN AND METHODS: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. RESULTS: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was −1.08 ± 0.06% (−11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −0.76 ± 0.06% (−8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and −0.63 ± 0.06% (−6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine. CONCLUSIONS: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic efficacies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than that of basal insulin (123-130).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“It is worth mentioning that in the AWARD-2 study, there were several cases of pancreatitis caused by DUL (112).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [112]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699 · cited 11×
“%) at least once after baseline; dulaglutide-neutralizing antibodies developed in 5, but no native sequence GLP-1neutralizing–antibodies developed.”
BackgroundInfluentialRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Thomas, G. E., Westfall, P. H., & Young, S. S. (1994) · The Statistician · doi:10.2307/2348369 · Cited by 513
Cited by
Items 101–200 of 269
Kugler, A. J., & Thiman, M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s134960 · Cited by 27
Wang, J., Li, H., Xu, X., Kong, X., Sun, R., Jing, T., Ye, L., Su, X., & Ma, J. (2019) · BioMed Research International · doi:10.1155/2019/2682657 · Cited by 27
“Similarly, AWARD-2 trial [18] found that on week 52, the total rate and the total times of hypoglycemia and nocturnal hypoglycemia of the glargine group were all higher than those of Dulaglutide groups.”
BackgroundResultAlexopoulos, A., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 27
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 24
Rados, D. R. V., Falcetta, M. R. R., Pinto, L. C. F., Leitão, C. B., & Gross, J. L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108688 · Cited by 25
Mannucci, E., Targher, G., Nreu, B., Pintaudi, B., Candido, R., Giaccari, A., Gallo, M., & Monami, M. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.03.007 · Cited by 23
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 24
“…in the exenatide comparator, without episodes of severe hypoglycemia [80], while a rate of 55.3% hypoglycemic events as compared to 69.1% in the insulin glargine comparator group, with similar rated of severe hypoglycemic events (2 events in each group) for dulaglutide in the AWARD-2 trial [81].”
BackgroundMethodResultInfluentialDulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers
Anderson, J. E., Thieu, V. T., Boye, K. S., Hietpas, R. T., & García‐Pérez, L. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1218260 · Cited by 23
“group with one patient on concomitant glimepiride and another who had previously discontinued glimepiride [27].”
BackgroundMethodInfluentialA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Gurung, T., Waugh, N. R., O’Hare, J. P., & Shyangdan, D. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34418 · Cited by 22
Billings, L. K., Handelsman, Y., HEILE, M. K., Schneider, D., & Wyne, K. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s30 · Cited by 31
Bain, E., & Bain, S. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 21
“with insulin glargine U100 (AWARD-2 and AWARD-4), there was a significant weight advantage for dulaglutide.(10,12) In AWARD-6, patients taking dulaglutide 1.”
BackgroundKaneko, S., Oura, T., Matsui, A., Shingaki, T., & Takeuchi, M. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0189 · Cited by 20
Chou, C., Chang, Y., Yang, J.-L., Wang, J., Lee, T.-E., Wang, R., & Hung, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16101-1 · Cited by 20
Van, J. T., Frías, J. P., Bonora, E., Raha, S., Meyer, J., Jung, H., Cox, D., Кониг, М., Peleshok, J. C., & Bethel, M. A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01140-9 · Cited by 20
Wysham, C., Guerci, B., D’Alessio, D. A., Jia, N., & Botros, F. T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12702 · Cited by 20
Pantalone, K. M., Patel, H., Yu, M. B., & Landó, L. F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13252 · Cited by 20
Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 21
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Le point sur un médicament : le dulaglutide (Trulicity®)
Bauduceau, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30025-2 · Cited by 19
Dyakov, I. N., & Zyryanov, S. K. (2021) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2021-2-4-15 · Cited by 18
Dungan, K. M., Raz, I., Skrivanek, Z., Sealls, W., & Fahrbach, J. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12575 · Cited by 18
“This was not unexpected, given that hypoglycaemia was generally mild and would not be captured with the definition of hypoglycaemia used in the present analysis [19].”
BackgroundMethodMode of administration of dulaglutide: implications for treatment adherence
Amblee, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s82866 · Cited by 17
“Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal.(22) Once-weekly dulaglutide 1.”
InfluentialDilla, T., Alexiou, D., Chatzitheofilou, I., Ayyub, R., Lowin, J., & Norrbacka, K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1275651 · Cited by 18
Mody, R., Huang, Q., Yu, M. B., Patel, H., Zhang, X., Wang, L., & Grabner, M. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000884 · Cited by 18
Dalmazi, G. D., Coluzzi, S., BALDASSARRE, M. P. A., Ghit, A., Graziano, G., Rossi, M. C., Ciappini, B., Milo, M., Carrieri, F., Nicolucci, A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892702 · Cited by 22
Yoo, J. H., Cho, Y. K., Lee, J., Kim, H. S., Kang, Y. M., Jung, C. H., Park, J., & Lee, W. J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0658-7 · Cited by 18
Miao, X., Davoudi, M., Alitotonchi, Z., Ahmadi, E. S., Amraee, F., Alemi, A., & Afrisham, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01581-3 · Cited by 20
“Dulaglutide also lowered the levels of HbA1c and body weight more than exenatide BID and insulin glargine in AWARD-1 and 2, with notable BW reductions [62–64].”
Ishii, H., Madin-Warburton, M., Strizek, A., Thornton‐Jones, L., & Suzuki, S. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1431918 · Cited by 16
Yan, L., Li, L., Peng, Y. D., Song, G., Ye, S., Du, L. Y., Hou, J. N., & Ji, Q. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0646-y · Cited by 17
Handelsman, Y., Wyne, K. L., Cannon, A. J., Shannon, M. H., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 20
Rigato, M., Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa178 · Cited by 15
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Basson, M., Ntais, D., Ayyub, R., Wright, D., Lowin, J., Chartier, F., Roze, S., & Norrbacka, K. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0321-0 · Cited by 15
“For this CUA treatment, efficacy and adverse event rates were based on data derived from a network meta-analysis (NMA) [16] and the AWARD-2 study [10].”
MethodDavidson, J. A., Manghi, F. P., Yu, M. B., Linetzky, B., & Landó, L. F. (2016) · Endocrine Practice · doi:10.4158/ep161337.or · Cited by 14
Gentilella, R., Sesti, G., Vázquez, L. A., Sapin, H., Reed, V. A., Romera, I., & Pozzilli, P. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13853 · Cited by 15
“The detailed methods used in each AWARD study have been previously published.(12-19)”
MethodXu, J., Zhang, Y., Li, Y., Zhao, X., Zhou, W., Loghin, C., Tham, L. S., Cui, X., Cui, Y., & Wang, W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01921-5 · Cited by 13
Lasalvia, P., Baquero, L., Esteban, M. O., Castañeda‐Cardona, C., & Rosselli, D. (2017) · Value in Health Regional Issues · doi:10.1016/j.vhri.2016.10.006 · Cited by 16
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Heile, M., Wyne, K., Billings, L., Cannon, A., Handelsman, Y., & Shannon, M. H. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s42 · Cited by 14
Shi, L., Liu, X. M., Yong Quan, S. H. I., Li, Q. M., Ma, J. H., Li, Y. B., Du, L. Y., Wang, F., & Chen, L. L. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13075 · Cited by 13
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 21
Aroda, V. R., Frías, J. P., Ji, L., Niemoeller, E., Nguyên‐Pascal, M., Denkel, K., Espinasse, M., Guo, H., Baek, S. J., Choi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15079 · Cited by 14
“Additionally, in AMPLITUDE-L and AMPLITUDE-S, participants were receiving SUs in background ( 44% and 51%, respectively), which is also known to cause hypoglycaemia, especially when combined with a GLP-1 RA.(19,25) Incidence of gastrointestinal AEs was higher in efpeglenatide treatment groups than with placebo, but co…”
ResultOsumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Giorgino, F., Yu, M., Haupt, A., Milicevic, Z., & García-Pérez, L. (2019) · Diabetes, obesity and metabolism · doi:10.1111/dom.13844 · Cited by 11
“explained by dulaglutide reducing both FG and PPG, as well as glucose levels throughout the day, as demonstrated across the phase 3 clinical trials with this GLP-1RA.(8,12-16) The superiority of dulaglutide 1.”
BackgroundMethodResultSelf-citationAdvances in the treatment of type 2 diabetes: impact of dulaglutide
Thompson, A., & Trujillo, J. M. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s75452 · Cited by 13
“Only in the AWARD-2 study did patients randomized to dulaglutide develop pancreatitis.(36) Two of these cases were acute, occurring 1 day and 302 days after the initiation of dulaglutide.”
BackgroundMethodResultInfluentialRose, T. N., Jacobs, M. L., Reid, D. J., Bouwmeester, C. J., Conley, M. P., Fatehi, B., Matta, T. M., & Barr, J. T. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.09.001 · Cited by 12
Franch-Nadal, J., Granado-Casas, M., Mata-Cases, M., Ortega, E., Vlacho, B., & Mauricio, D. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.10.005 · Cited by 12
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
“Dulaglutide demonstrated non-inferiority compared with liraglutide [52] and greater reductions in HbA1c when compared with exenatide, insulin glargine, and sitagliptin (Table 7) [47-50,52,86].”
BackgroundRationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
“ment resulted in reductions in 2-h PPG concentration after 52 weeks [83].”
Gentilella, R., Romera, I., Nicolay, C., Buzzetti, R., Vázquez, L. A., & Sesti, G. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0625-3 · Cited by 12
Pollock, R. F., Norrbacka, K., Cameron, C. G., Mancillas‐Adame, L. G., & Jeddi, M. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0073 · Cited by 12
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 13
“The consistently lower rates of hypoglycaemia reported with dulaglutide compared with insulin are therefore of important clinical significance, particularly given the improved glycaemic control with dulaglutide [7].”
BackgroundInfluentialMeece, J. D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0491-1 · Cited by 16
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
Chu, L., Bradley, R., Auerbach, P., & Abitbol, A. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.15834 · Cited by 11
Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
Patel, D. K. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000112 · Cited by 10
“AWARD-2; 78 weeks (Giorgino et al., 2015) Metformin, glimepiride Dulaglutide, insulin glargine 20.”
BackgroundQie, S., Li, X., Wang, X., Liu, Y., Li, J., & Liu, G. (2020) · Endocrine · doi:10.1007/s12020-020-02193-9 · Cited by 12
Wang, W., Huang, F., & Han, C. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01459-5 · Cited by 13
Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”
Cefalu, W. T., Rosenstock, J., LeRoith, D., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dci15-0023 · Cited by 10
“(7) reported on the use of oral agents in”
BackgroundIs insulin the preferred treatment for HbA1c >9%?
Bloomgarden, Z. T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12575 · Cited by 10
“ing dulaglutide with insulin glargine also showed a superior HbA1c-lowering effect of the former.(18)”
BackgroundZupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Xu, J., Yao, D., & Xia, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13398 · Cited by 11
Exacerbation of atrial fibrillation related to dulaglutide use
Lee, J., Umana, I. E., & Nguyen, J. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4223 · Cited by 9
The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
Ruda, A. I., Ciobanu, D. M., Inceu, G., Rusu, A., & Román, G. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2425 · Cited by 9
“type 2 diabetes due to its proven effectiveness in enhancing glycemic control in the AWARD (Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes) clinical program [7,9-17] and reducing cardiovascular risk in the REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) clinica…”
BackgroundMethodGLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
Gallwitz, B. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.01.21 · Cited by 9
Umpierrez, G., Pantalone, K., Atisso, C., Landó, L. F., & Patel, H. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13662 · Cited by 7
Mody, R., Yu, M. B., Grabner, M., Boye, K. S., Teng, C., & Kwan, A. Y. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.011 · Cited by 10
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Guo, L., Zhang, B., Hou, J., & Zhou, Z. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00869-z · Cited by 8
Peptibodies: Bridging the gap between peptides and antibodies
Khezri, H., Mostafavi, M., Dabirmanesh, B., & Khajeh, K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134718 · Cited by 10
Bobu, A. M., Turliuc, Ș., Cucu, A. I., Onofriescu, A., Dascălu, C. G., Costea, C. F., Pătrășcanu, E., Morosan, A. P., Hăisan, A., Filip, C. N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103536 · Cited by 7
“For example, its effectiveness in reducing HbA1c is greater when added to metformin compared to basal insulin [17].”
Patel, H., Munir, K. M., Sutherland, S.-B., Karanikas, C. A., & Кониг, М. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00709-9 · Cited by 7
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Wasir, J. S., Mithal, A., Agarwal, P., & Mittal, A. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_424_18 · Cited by 8
Zheng, S., Polidori, D., Wang, Y., Geist, B. J., Lin‐Schmidt, X., Furman, J. L., Nelson, S., Nawrocki, A. R., & Hinke, S. A. (2023) · Clinical and Translational Science · doi:10.1111/cts.13543 · Cited by 8
Boye, K. S., Mody, R., Wu, J., Lage, M. J., Botros, F. T., & Woodward, B. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.002 · Cited by 7
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Lee, E. Y., Cho, J., Lee, W. J., Kim, N. H., Kim, J. H., & Lee, B. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110884 · Cited by 6
Rajagopal, D., Rashid, S. A., Prasad, M., & Fareed, M. (2024) · Cureus · doi:10.7759/cureus.65910 · Cited by 12
“Albiglutide has demonstrated comparable effectiveness to other GLP-1 receptor agonists concerning managing blood sugar levels and promoting weight loss [11].”
BackgroundLv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
Khan, A. B., Shah, A., Ahmad, S., Khan, M. I., & Amir, A. (2023) · Cureus · doi:10.7759/cureus.38630 · Cited by 8
Busch, R. S., Ruggles, J., Han, J., & Hardy, E. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13029 · Cited by 6
Poon, J. L. (2018) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2018.06.555700 · Cited by 6
Rados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Duque, N., Artime, E., Romera, I., Lebrec, J., Díaz‐Cerezo, S., Rubio, M., Sicras‐Mainar, A., Carretero-Anibarro, E., Mundet, X., Martínez, J. J. G., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01773-z · Cited by 7
“Based on an IGlar daily dose SD of 25 units [23], a sample size of 500 per cohort would allow detection of a difference in glargine dose of C 5.”
BackgroundPréparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12091943 · Cited by 5
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 7
Takehisa, Y., & Bando, H. (2020) · Edelweiss Journal of Biomedical Research and Review · doi:10.33805/2690-2613.113 · Cited by 5
Yoon, J. H., Hong, A. R., Choi, W., Park, J. Y., Kim, H. K., & Kang, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.3.211 · Cited by 5
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Surpassing insulin glargine in type 2 diabetes with tirzepatide
Khoo, B. C. E., & Tan, T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02279-0 · Cited by 5
Jódar, E., Romera, I., Wang, Q., Roche, S. L., & García‐Pérez, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14615 · Cited by 5
“6 mmol/L.(29) At 26 weeks, the daily dose of glargine (mean ± standard deviation [SD]) was (last observation carried forward [LOCF]) 26 ± 24 units (0.”
BackgroundUgamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Renal Replacement Therapy · doi:10.1186/s41100-022-00409-4 · Cited by 4
Giorgino, F., Franco, D. R., Nicolay, C., Hemmingway, A., Rodríguez, Á., & Wiese, R. J. (2024) · Diabetes Care · doi:10.2337/dc23-2366 · Cited by 7
Self-citation
Metadata
- Authors
- Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V.
- Affiliations
- University of Bari Aldo Moro (IT)
- Evangelismos-Polyclinic, Athens General Hospital, Athens, Greece
- Chang Gung Memorial Hospital (TW)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Neuilly-Sur-Seine Cedex, France
- Corresponding author
- Pechtner, Valeria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-06-18
- Volume
- 38
- Issue
- 12
- Pages
- 2241-2249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W906438903
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 17 · 2023: 20 · 2022: 19 · 2021: 21 · 2020: 22 · 2019: 28 · 2018: 29 · 2017: 27 · 2016: 23 · 2015: 17
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, insulin glargine, type 2 diabetes, GLP-1 receptor agonists, metformin, glimepiride, HbA1c, glycemic control, non-inferiority, hypoglycemia, body weight, pancreatic enzymes, nausea, drug safety, dose comparison
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Recombinant Fusion Proteins, Sulfonylurea Compounds, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.